search
  • Country
    Clear
  • Thematic
    Clear
  • Type
  • Compatibility Level
  • Jurisdiction
4,705 Data sources

  • GB
  • IN
  • CA
  • Thematic: No

  • more_vert
  • more_vert
  • This repository hosts the research output of the institution. The interface is available in English.

    more_vert
  • This site provides access to documents authored by NRC employees. Some items are not available as full text; where available, alternative locations to obtain documents may be provided. The interface is in French and English.

    more_vert
  • more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • College repository providing open access to the research output of the institution.

    more_vert
  • chevron_left
  • 9
  • 10
  • 11
  • 12
  • 13
  • chevron_right
4,705 Data sources
  • more_vert
  • more_vert
  • This repository hosts the research output of the institution. The interface is available in English.

    more_vert
  • This site provides access to documents authored by NRC employees. Some items are not available as full text; where available, alternative locations to obtain documents may be provided. The interface is in French and English.

    more_vert
  • more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • College repository providing open access to the research output of the institution.

    more_vert
  • chevron_left
  • 9
  • 10
  • 11
  • 12
  • 13
  • chevron_right